Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>hSMG-1 inhibitor 11j

hSMG-1 inhibitor 11j

Katalog-Nr.GC61925

Der hSMG-1-Inhibitor 11j, ein Pyrimidinderivat, ist ein potenter und selektiver Inhibitor von hSMG-1 mit einem IC50-Wert von 0,11 nM. Der hSMG-1-Inhibitor 11j zeigt eine >455-fache SelektivitÄt fÜr hSMG-1 gegenÜber mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) und CDK1/CDK2 (IC50=32/7,1 μM). Der hSMG-1-Inhibitor 11j kann fÜr die Krebsforschung eingesetzt werden.

Products are for research use only. Not for human use. We do not sell to patients.

hSMG-1 inhibitor 11j Chemische Struktur

Cas No.: 1402452-15-6

Größe Preis Lagerbestand Menge
5 mg
450,00 $
Auf Lager
10 mg
765,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 µM). hSMG-1 inhibitor 11j can be used for the research of cancer[1].

hSMG-1 inhibitor 11j (0.3-3 µM; 6 h) significantly reduces UPF1 phosphorylation at 0.3 µM, and eliminates it at 1 µM in MDA 361 cells[1].hSMG-1 inhibitor 11j inhibits MDA468 cell proliferation, with an IC50 of 75 nM[1].

References:
[1]. Gopalsamy A, et, al. Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41.

Bewertungen

Review for hSMG-1 inhibitor 11j

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for hSMG-1 inhibitor 11j

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.